Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.04.01

Making sanitizers available during COVID-19 outbreak

Making sanitizers available during COVID-19 outbreak

Over the past few weeks since the outbreak of COVID-19, there’s been a sudden rise in sanitization efforts by various public and private organizations to help arrest the spread of the disease. This, along with efforts of individuals in their own spaces, has created a huge demand for effective alcohol-based sanitizers to aid the sanitization efforts.

Noticing the constrained supply of sanitizers, Sai Life Sciences commenced the production of alcohol-based sanitizer and surface cleaners as per WHO guidelines, and is making them available free of cost to the various organizations leading the sanitization efforts.

Over the past week, the Sai Life Sciences team has distributed over 4000 litres of hand sanitizers to various public organizations including –

  • Cyberabad Police Commissionerate, Hyderabad
  • Bidar Air Force Station
  • Bidar Institute of Medical Sciences
  • District Health Department, Bidar
  • Bidar District Police
  • Bidar District Administration
  • Bidar Municipal office

The sanitizers have also been distributed in the Bellura and Kolhar Villages of Bidar district, in addition to the families of Sai Life Sciences employees.

While helping prevent the spread of COVID-19 through better hygiene & sanitization, the efforts have also been personally gratifying for the Sai employees who have been involved in making it happen.

Since the outbreak of the COVID-19, Sai Life Sciences has taken several proactive measures to protect its employees and their families, and to minimize the impact on its partners, customers and the community. You can read the detailed report here.

Share article

More News

2025.10.08

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators

Manchester/Hyderabad, October 08, 2025: Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API […]
Read more

2025.10.06

Unlocking Chemical Frontiers: IIT Bombay Prof, Debabrata Maiti at Sai Life Sciences

As part of Sai Life Sciences’ efforts to foster knowledge exchange and bring leading voices from niche areas of science and technology to its teams, the company recently hosted Prof. Debabrata Maiti from the Indian Institute of Technology (IIT) Bombay at its R&D campus in Hyderabad for a day of scientific exchange and dialogue. The […]
Read more

2025.09.18

Sai Life Sciences opens dedicated facility for Veterinary APIs in Bidar, India

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for veterinary API production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. The new […]
Read more

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more